The agency has granted the drug and CDx priority review, which Myriad expects to conclude during its fiscal third-quarter ending March 31, 2018.
September was the third consecutive month in which the index barely moved month over month. NantHealth paced the gainers, while Quest Diagnostics paced the decliners.
The investment firm noted that Myriad is still trying to stabilize its hereditary cancer testing business while diversifying its portfolio to drive future growth.
Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.
The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today.
Amid a flat month for the index, some firms saw large swings in their stock price. Natera led the gainers, while NantHealth led the decliners.
Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.
During an earnings call, company executives discussed plans to grow reimbursement of new tests, stabilize pricing, and save costs through a number of projects.
The increase in overall fourth quarter sales was due to contributions from new products in the company's portfolio.
NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.